MDR-TB Care and Treatment

The MDR-TB care and treatment agreement is to build upon the Bedaquiline donation program as well as respond to the White House National Action Plan to Combat MDR-TB Goal 2 milestones. The public-private partnership between USAID and Janssen Therapeutics of Johnson & Johnson is providing new care and treatment options to the highest burden countries through innovative approaches. Because MDR-TB is highly contagious and notoriously difficult to treat, it is critical to develop innovative solutions to curb this epidemic. Bedaquiline, developed by USAID's partner Janssen Pharmaceuticals (of parent company, Johnson & Johnson), is the first new class of antibiotics that has been U.S. Food and Drug Administration (FDA) approved in more than 40 years. The use of this drug in combination with existing second-line drugs and the new WHO approved shortened regimen provides new hope for MDR-TB patients with limited treatment options. However, it requires system and program changes. This activity will introduce and improve patient centered care packages, pharmacovigilence systems, treatment options and training at all levels.
Implementing Partner 
USAID is serving as the implementing partner by expanding existing platforms and programs to improve MDR-TB care and treatment
Total Lifetime Investment 
$ 5,500,000.00
USG Investment 
$ 5,000,000.00
Non-USG Investment 
$ 500,000.00
Resource Partner 
Activity Sector 
Start Year 
End Year